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Summary
Background Surgery is increasingly used as treatment for refractory focal epilepsy; however, few rigorous reports of 
long-term outcome exist. We did this study to identify long-term outcome of epilepsy surgery in adults by establishing 
patterns of seizure remission and relapse after surgery.
Methods We report long-term outcome of surgery for epilepsy in 615 adults (497 anterior temporal resections, 40 temporal 
lesionectomies, 40 extratemporal lesionectomies, 20 extratemporal resections, 11 hemispherectomies, and seven palliative 
procedures [corpus callosotomy, subpial transection]), with prospective annual follow-up for a median of 8 years (range 1–19). 
We used Kaplan-Meier survival analysis to estimate time to ﬁ rst seizure, and investigated patterns of seizure outcome.
Findings We used survival methods to estimate that 52% (95% CI 48–56) of patients remained seizure free (apart from 
simple partial seizures [SPS]) at 5 years after surgery, and 47% (42–51) at 10 years. Patients who had extratemporal 
resections were more likely to have seizure recurrence than were those who had anterior temporal resections (hazard 
ratio [HR] 2·0, 1·1–3·6; p=0·02); whereas for those having lesionectomies, no diﬀ erence from anterior lobe resection 
was recorded. Those with SPS in the ﬁ rst 2 years after temporal lobe surgery had a greater chance of subsequent 
seizures with impaired awareness than did those with no SPS (2·4, 1·5–3·9). Relapse was less likely the longer a 
person was seizure free and, conversely, remission was less likely the longer seizures continued. In 18 (19%) of 
93 people, late remission was associated with introduction of a previously untried antiepileptic drug. 
104 of 365 (28%) seizure-free individuals had discontinued drugs at latest follow-up.
Interpretation Neurosurgical treatment is appealing for selected people with refractory focal epilepsy. Our data provide 
realistic expectations and indicate the scope for further improvements in presurgical assessment and surgical 
treatment of people with chronic epilepsy.
Funding UK Department of Health National Institute for Health Research (NIHR) Biomedical Research Centres 
funding scheme, Epilepsy Society, Dr Marvin Weil Epilepsy Research Fund.
Introduction
Surgical treatment for focal epilepsy has been increasingly 
used.1 The only randomised controlled trial2 of surgery 
established the short-term beneﬁ ts of anterior temporal 
lobe resection compared with medical treatment for 
refractory temporal epilepsy. Chances of seizure 
remission after surgery in an individual with concordant 
data are generally about 60–70%.1 In one study3 of long-
term outcome in 325 people having anterior temporal 
resection, the rate of seizure freedom was 41% at 10 years. 
Patients who were seizure free 2 years postoperatively 
had a 74% (95% CI 66–81) probability of seizure freedom 
by 10 postoperative years. Late recurrence after initial 
seizure freedom was not uncommon, and risk factors 
associated with such recurrence are unknown.
Our aim was to follow up patients postoperatively to 
identify patterns of seizure remission and relapse after 
surgery, to enable individuals considering surgery to 
make informed choices.
Methods
Study design and participants
We identiﬁ ed the long-term outcome and patterns of 
seizure remission and relapse up to Nov 19, 2009, in 
649 consecutive people undergoing epilepsy surgery at 
the National Hospital for Neurology and Neurosurgery 
(NHNN), London, UK, from Feb 15, 1990, to Oct 30, 
2008. Two consultant neurosurgeons specialising in 
epilepsy (WFJH and AWMcE) did more than 90% of 
operations. For every person, clinical and investi gatory 
data were considered in detail (ie, clinical history; 
examination; seizure semiology; interictal and ictal 
electroencephalogram; MRI; neuropsychological and 
psychiatric assess ment; and when location of the 
epileptogenic zone was unclear, and to help predict risk 
of deﬁ cit, functional MRI [language and motor], carotid 
amytal, single-photon-emission CT, and PET were 
investigated). The optimum surgical approach was then 
derived to provide the best chance of seizure freedom 
with the lowest risk of complications.4 The general 
principles of presurgical assessment in our unit were 
established in 1990, and, although advances have been 
made in MRI and video electroencephalography-
recording technology, the principles for establishing a 
consensus of data for the zone of seizure onset and the 
relation to eloquent cortex have not changed.4
Information for yearly updates of seizure status was 
obtained from review of contemporaneous NHNN 
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notes and from notes of other hospitals people were 
attending. We supplemented these data with direct 
annual inquiry by a neurology consultant and clinical 
data manager who contacted the individuals and their 
general practitioners and, in cases of uncertainty, 
patients’ next of kin. Speciﬁ c questions were the 
occurrence of simple partial seizures (SPS), seizures 
with loss of awareness, and antiepileptic drugs taken. 
When there were discrepancies between sources, 
further inquiries were made until a consensus was 
reached. We classiﬁ ed seizure outcomes for each 
postsurgical year (outcome classiﬁ cation) with the 
International League Against Epilepsy (ILAE) surgery 
outcome scale5 (panel 1). We use the term SPS 
throughout, which incorporates all events that are 
sometimes classiﬁ ed as auras. We noted the use of 
antiepileptic drugs and changes within each previous 
year. An outcome classiﬁ cation of class 3 (OC3) or 
greater deﬁ ned the occurrence of seizures other than 
SPS. Distinction between OC4 and OC5 might be more 
diﬃ  cult and this distinction was not analysed. This 
study was approved by the Joint Ethics Committee of 
the National Hospital for Neurology and Neurosurgery 
and University College London Institute of Neurology. 
The Research Ethics Committee classiﬁ ed this work as 
a service evaluation, therefore individual consent from 
patients was not needed.
Statistical analysis
Survival analysis with Cox proportional hazard re-
gression was used for all time-to-event outcomes and to 
compare time to ﬁ rst seizure (≥OC3). Hazard ratios 
(HRs) were calculated with 95% CIs. Age at surgery was 
included in the analyses when appropriate. We used the 
Kaplan-Meier method to estimate the proportion of 
individuals remaining seizure free at various time-
points. Analyses were done comparing diﬀ erent 
pathological changes in people with similar surgical 
procedures, and diﬀ erent surgical procedures in people 
with similar changes. For one analysis, we selected 
those who had no seizures or SPS only in the ﬁ rst 
2 postoperative years and analysed time to ﬁ rst seizure 
(≥OC3). See webappendix for analysis of time to ﬁ rst 
seizure including SPS (≥OC2).
We did statistical analysis using Stata version 10, and 
95% CIs for proportions were obtained from Conﬁ dence 
Interval Analysis software (version 2.1.2).6
Role of the funding source
This work was done at the Epilepsy Society and 
University College London Hospitals/University College 
London Comprehensive Biomedical Research Centre, 
which receives partial funding from the UK Department 
of Health’s NIHR Biomedical Research Centres funding 
scheme. The sponsor had no involvement in the design, 
collection, analysis, data interpretation, or writing of 
the Article.
Results
No yearly outcome scores were available for 34 of 649 
(5%) people because of death (n=5) or loss to follow-up 
(27) within 1 year of surgery (15 of these 27 lived overseas), 
or because they had subsequent surgery within 1 year of 
the ﬁ rst operation (2). Thus, 615 people (287 men, aged 
16–63 years at surgery, median duration of epilepsy 
before surgery 20·7 years [IQR 13·9–28·6]) are 
considered further. Table 1 shows pathological changes 
and surgical procedures. For 15 people who had two 
surgical procedures for epilepsy, data were censored at 
the time of the second procedure. We included 19 people 
who had had previous neurosurgical procedures 
(17 biopsy or partial lesion removal, one meningioma 
removal, one partial corpus callosal section). With 
5241 person-years of follow up, data for outcome 
classiﬁ cations were available for a median of 8 years 
(range 1–19). Data were not available for the 2 years 
before the audit date (Nov 19, 2009) in 127 (21%) people 
for whom the last veriﬁ ed follow-up data were obtained 
before Nov 19, 2007. The median duration of follow-up 
for these 127 people was 6 years (range 1·2–17·5).
We estimated by survival analysis the probability of 
being entirely seizure free at 2 years as 49% (webappendix). 
63% (95% CI 59–67) of the whole cohort remained seizure 
Panel 1: Outcome after epilepsy surgery5
• OC1: seizure free
• OC2: SPS only—ie, no other seizures
• OC3: Seizures on less than 4 days per year, with or 
without SPS
• OC4: More than 50% reduction in numbers of days 
aﬀ ected by seizures with or without SPS
• OC5: No signiﬁ cant change in seizures with up to 
50% reduction ranging to 100% increase in days aﬀ ected 
by seizures
• OC6: More than 100% increase in days aﬀ ected by seizures
OC=outcome classiﬁ cation. SPS=simple partial seizures.
ATLRx Tlesx ETlesx ETLx Hx Palliative Total 
Hippocampal sclerosis 407 0 0 0 0 0 407
Dysembryoplastic 
neuroepithelial tumour
36 20 16 7 0 0 79
Cavernoma 18 6 8 1 0 0 33
Glioma 5 7 11 1 0 0 24
Focal cortical dysplasia 3 3 4 5 0 0 15
Gliosis 9 2 1 4 5 1 22
Other 19 2 0 2 6 6 35
Total (%) 497 (81%) 40 (7%) 40 (7%) 20 (3%) 11 (2%) 7 (1%) 615
Data are number (%). ATLRx=anterior temporal lobe resection. Tlesx=temporal lesionectomy. ETlesx=extratemporal 
lesionectomy. ETLx=extratemporal lobe resection. Hx=hemispherectomy.
Table 1: Surgical procedures and pathological ﬁ ndings in study population
See Online for webappendix
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free (other than SPS) 2 years after surgery, 52%  (48–56) 
after 5 years, and 47% (42–51) after 10 years. Table 2 shows 
univariable and multivariable survival analysis of time to 
ﬁ rst seizure (≥OC3) after surgery, and the probability of 
seizure freedom after 10 years. Multivariable results 
include all factors that were statistically signiﬁ cant in 
univariable models. Age at surgery had a signiﬁ cant eﬀ ect 
on outcome (table 2) and was included in all subsequent 
analyses. 5 years after surgery, the seizure-free rates 
(excluding SPS) were 55% (95% CI 51–60) for anterior 
temporal resection, 56% (38–70) for temporal lesion-
ectomy, 40% (24–55) for extratemporal lesionectomy, and 
64% (30–85) for hemi spherectomy (ﬁ gure 1). 
A diﬀ erence in outcome was noted for the various 
pathological changes after anterior temporal resection 
(p=0·02; table 3). Those with focal cortical dysplasia and 
those with other changes, including other malformations 
and no detected abnormality, had signiﬁ cantly earlier 
relapses than did those with hippocampal sclerosis. The 
5-year seizure-free rates (excluding SPS) for anterior 
temporal resection were 57% (95% CI 52–62) for those 
with hippocampal sclerosis, and 63% (45–77) for those 
with dysembryoplastic neuroepithelial tumour. 
In those who had a lesionectomy, the risk of seizure 
recurrence did not signiﬁ cantly diﬀ er in patients with 
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Figure 1: Kaplan-Meier analysis of time to ﬁ rst seizure (excluding SPS), by operation type
Palliative procedures not shown because of small numbers of patients. SPS=simple partial seizures. ATLRx=anterior 
temporal resection. TLesx=temporal lesionectomy. ETLesx=extratemporal lesionectomy. ETLx=extratemporal 
resection. Hx=hemispherectomy.
Univariable analysis (unadjusted) Estimated percentage seizure 
free at 10 years (unadjusted)
Multivariable analysis* 
(p=0·0003)
HR (95% CI) p value % (95% CI) HR (95% CI)
Age at surgery (1-year increment) 1·01 (1·00–1·02) 0·039 ·· 1·01 (1·00–1·03)
Age at surgery (5-year increment) 1·06 (1·00–1·13) ·· ·· 1·07 (1·01–1·14)
Operation type (n=615) 0·0004
Anterior temporal resection (n=497) 1 (··) ·· 49% (44–54) 1 (··)
Temporal lesionectomy (n=40) 0·93 (0·57–1·52) ·· 56% (38–70) 0·78 (0·44–1·37)
Extratemporal lesionectomy (n=40) 1·55 (1·03–2·32) ·· 31% (16–48) 1·37 (0·82–2·31)
Extratemporal resection (n=20) 2·79 (1·69–4·59) ·· ·· 2·00 (1·12–3·59)
Hemispherectomy (n=11) 0·73 (0·27–1·96) ·· ·· 0·47 (0·16–1·38)
Palliative (n=7) 3·35 (1·57–7·14) ·· ·· 2·03 (0·86–4·76)
Pathological ﬁ ndings (n=615) 0·012
Hippocampal sclerosis (n=407) 1 (··) ·· 51% (45–56) 1 (··)
DNT (n=79) 1·17 (0·83–1·64) ·· 42% (29–55) 1·15 (0·76–1·74)
Cavernoma (n=33) 1·25 (0·75–2·08) ·· 45% (25–63) 1·08 (0·61–1·90)
Glioma (n=24) 1·37 (0·79–2·35) ·· 42% (20–62) 1·26 (0·66–2·40)
Focal cortical dysplasia (n=15) 2·34 (1·27–4·31) ·· ·· 1·88 (0·93–3·82)
Gliosis (n=22) 1·95 (1·17–3·26) ·· .. 1·90 (1·07–3·37)
Other (n=35)† 1·82 (1·18–2·81) ·· .. 1·81 (1·08–3·01)
We estimated percentages from the survival curve. ≥OC3=Outcome classiﬁ cation class 3. HR=hazard ratio. DNT=dysembryoplastic neuroepithelial tumour. *All other factors 
in the model—ie, age at surgery, operation type, and pathology. †Dual pathology, no abnormalities, malformations, other focal abnormalities, and other abnormalities.
Table 2: Univariable and multivariable survival analysis of time to ﬁ rst seizure (≥OC3)
HR (95% CI)
Hippocampal sclerosis (n=407) 1 (··)
Dysembryoplastic neuroepithelial 
tumour (n=36)
0·89 (0·51–1·53)
Cavernoma (n=18) 1·18 (0·58–2·40)
Glioma (n=5) 1·22 (0·39–3·82)
Focal cortical dysplasia (n=3) 3·60 (1·15–11·3)
Gliosis (n=9) 2·05 (0·96–4·37)
Other including malformations and no 
detected abnormality (n=19)
2·09 (1·21–3·61)
HR=hazard ratio. 
Table 3: Eﬀ ect of pathological ﬁ ndings on time to ﬁ rst seizure after 
temporal lobe resections, allowing for age at surgery
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a glioma (n=18) or dysembryoplastic neuroepithelial 
tumour (36) compared with those with a cavernoma (14) 
(HR 1·42, 95% CI 0·58–3·47). No diﬀ erence in probability 
was noted between patients with glioma, dysembryoplastic 
neuroepithelial tumour, or cavernoma, compared with 
those with focal cortical dysplasia (n=7; HR 0·77, 
0·27–2·17).
In people with glioma, dysembryoplastic neuroepithelial 
tumour, cavernoma, or focal cortical dysplasia, time to 
ﬁ rst seizure did not diﬀ er between those who underwent 
anterior temporal resection (n=62) or temporal lesion-
ectomy (36; HR for lesionectomy 0·92, 0·49–1·73). 
Results were similar for individual pathological changes, 
but numbers were small. 
40 people had temporal lesionectomies and 40 had 
extratemporal lesionectomies. The time to ﬁ rst seizure 
was not diﬀ er ent between the two groups (HR for 
extratemporal lesionectomy 1·7, 0·9–3·1). This ﬁ nding 
was not materially altered (1·8, 0·95–3·5) when type of 
pathological change was included in the analysis. 
296 people with further follow-up had anterior temporal 
surgery and no seizures (or SPS only) in the ﬁ rst 2 years 
after surgery. The 73 individuals who had SPS in this 
time were signiﬁ cantly more likely to have a seizure 
(≥OC3) in the subsequent years than were those who had 
no SPS (HR 2·4, 1·5–3·9; ﬁ gure 2, table 4). 
At each annual review 68–73% of people were seizure 
free or had SPS only. Although the overall proportion 
remaining seizure free was fairly stable, 3–15% changed 
between groups each year (ﬁ gure 3). Table 5 shows the 
probability of remaining seizure free after initial seizure 
freedom—the longer a person stayed seizure free, the less 
likely they were to relapse. The latest relapse in somebody 
previously seizure free was at 15 years after surgery. In 
people with postoperative seizures (table 6), subsequent 
remission was less likely the longer seizures continued.
Patterns of seizure remission and relapse in the total 
cohort (N=615) were stratiﬁ ed into eight groups (A–G, 
table 7). Deaths were noted and classiﬁ ed as not epilepsy 
related or probably epilepsy related. 451 (73%) patients 
had at least 1 year of absolute seizure freedom, and 
505 (82%) had at least 1 year with no seizures or SPS 
only. In ten of 47 people (group C) who relapsed after 
1 year or more without seizures, the relapse was 
preceded by tapering or omission of antiepileptic drugs. 
In a further nine, relapse was associated with stress or 
intercurrent illness. In 36 of 49 (73%) people with 
seizures initially continuing postsurgically (group B), 
remission occurred with no changes in antiepileptic 
drugs. 30 of these 49 (61%) people who continued to 
have seizures after surgery went into long-term 
remission 2 years after surgery, and the remainder did 
so after 3–14 years. A further 44 went into remission, 
had a subsequent short-lived relapse, and then terminal 
remission (group D). In 18 people from groups B and D, 
seizure remission occurred at 2–12 years after surgery 
following the introduction of a previously unused 
antiepileptic drug (14 levetiracetam, one clobazam, one 
pregabalin, one topiramate, one valproate). A further 
14 people from group D who had seizures after 
withdrawal of anti epileptic drugs went into long-term 
remission after restarting the drugs.
For people who were seizure free after surgery, the 
possibilities of reductions in antiepileptic drugs were 
discussed in accordance with their circumstances. At 
latest follow-up, 104 of 365 (28%) seizure-free individuals 
No seizures in ﬁ rst 
2 years (95% CI)
SPS only in ﬁ rst 
2 years (95% CI)
2 years later 89% (84–92) 81% (70–89)
5 years later 86% (80–90) 67% (54–77)
10 years later 78% (71–84) 55% (41–67)
SPS=simple partial seizure.
Table 4: Estimated percentage of patients remaining free of seizures with 
loss of awareness (with 95% CIs) at intervals after temporal surgery in 
patients who did, and did not have, SPS in ﬁ rst 2 years after surgery
Seizures this year, seizure free next year
Seizures this year and subsequent year
Seizure free this year, seizures next year
Seizure free this year and subsequent year
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Figure 3: Patients seizure free (OC1 and OC2) and not seizure free (≥OC3) after epilepsy surgery
Darker blocks represent patients who remained in the same seizure status (seizure free or not seizure free) in the 
subsequent year. Lighter areas represent those who changed seizure status (from seizure free to having seizures, or 
from continuing seizures to seizure freedom) in the subsequent year. OC=outcome classiﬁ cation.
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Figure 2: Time to ﬁ rst seizure after temporal lobe surgery in people who had no seizures at all, or who had SPS 
only, in the ﬁ rst 2 postoperative years
SPS=simple partial seizures.
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were oﬀ  these drugs. Four of 65 (6%) people with SPS at 
last follow-up, and ﬁ ve of 185 (3%) with continuing 
seizures were taking no antiepileptic drugs. 
Mortality was reported previously in patients who were, 
and were not, seizure free after surgery.7 19 of the 
615 (3%) people died (ﬁ ve deaths were epilepsy related, 
11 non-epilepsy related, and three of unknown cause), in 
addition to the ﬁ ve people who died within 1 year of 
surgery (one cancer death, one infection-related death, 
one suicide, and two sudden expected deaths in epilepsy 
[SUDEP]). These results approximate to one death per 
218 patient-years of follow-up. Clinically evident morbidity 
caused by the surgical procedures consisted of 46 superior 
quadrant visual ﬁ eld defects (8% of temporal lobe 
procedures); 28 (5%) wound infections needing anti-
biotics; three (<1%) hemipareses; 15 (2%) cases of front-
alis muscle weakness; six (1%) cases of dysphasia; 
19 (3%) cerebrospinal ﬂ uid leaks needing resuturing; and 
one deep venous thrombosis needing anticoagulation.
Discussion
We established long-term outcome and use of antiepileptic 
drugs in a large adult epilepsy surgery cohort with more 
than 5200 person-years of follow-up. Half the individuals 
were seizure free in terms of usually cited criteria—
ie, entirely seizure free or SPS only—for the duration of 
follow-up, and 40% were completely seizure free 
throughout follow-up. At any time, nearly three-quarters 
of people were seizure free in the previous year (ﬁ gure 3). 
Age at surgery had a small eﬀ ect (HR 1·01) with about a 
6% increased risk of seizure recurrence in adults who 
were 5 years older at surgery, and a 13% increased risk in 
people 10 years older.
Previous studies of seizure outcome at year 1, year 2, and 
at last follow-up do not capture all the outcomes of 
seizure control after surgery.8 Other workers1,8 have used 
diﬀ ering outcome classiﬁ cations and deﬁ nitions of 
seizure freedom. We used the ILAE classiﬁ cation5 and 
analysed OC1 (entirely seizure free in the previous year, 
panel 1, webappendix), and OC1 and OC2 (including 
SPS). Individuals kept prospective seizure diaries and 
would have known if they had had seizures on more than 
3 days in a year.
One study9 had a 60% response to a questionnaire done 
on average 7 years after temporal surgery, and showed 
that 48% of patients had not had seizures since surgery, 
which is somewhat better than the 38% entirely seizure-
free individuals in our cohort 10 years after anterior 
temporal resection, as estimated by survival analysis. The 
poor response rate of the questionnaire raises the 
possibility of bias. Another study10 has shown that, after 
surgery, 43% of patients were seizure free or had SPS 
throughout a mean 7-year follow-up, whereas others3,11,12 
of people with temporal surgery followed up for a mean 
of 5–10 years reported seizure freedom (with or without 
SPS) of between 41% and 63%.
In our cohort, the probability of remaining seizure 
free (no seizures with loss of awareness) was 63% at 
2 years. By 10 years the probability of remaining seizure 
free or with SPS was 47%, or 37% entirely seizure free. 
A study13 in consecutive people with temporal resection 
for hippo campal sclerosis estimated that 77% were 
seizure free at 2 years, and 74% at 5 years. Although the 
success rate in that study seems higher than that in our 
study, numbers were small and 95% CIs not provided. 
Unsurprisingly, others14 have noted that a short interval 
between surgery and ﬁ rst seizure recurrence was 
associated with a worse longer-term prognosis than a 
longer interval.
N (%) Median (range) 
duration of follow-up 
(years)
A: Seizure free or SPS only since surgery 315 (51%) 7 (1–17)
Entirely seizure free 245 (40%) 7 (1–17)
SPS only 70 (11%) 10 (1–17)
B: Seizures initially then terminal remission 49 (8%) 9 (2–19)
C: Initial seizure freedom then relapse 47 (8%) 11 (2–17)
D: Seizure freedom with transient relapse then terminal remission 44 (7%) 10 (3–18)
E: Never seizure-free 110 (18%) 7 (1–19)
F: Complex pattern of remissions and relapses 37 (6%) 12 (4–17)
G: Seizures initially then a period of seizure freedom, then relapse 13 (2%) 11 (3–15)
SPS=simple partial seizure.
Table 7: Patterns of seizure remission and relapse after surgery
Seizure free for 
2 years after 
surgery (n=323)
Seizure free for 
5 years after 
surgery (n=208)
Seizure free for 
10 years after 
surgery (n=100)
1-year SFU 92% (88–94) 97% (94–99) 99% (93–100)
2-year SFU 87% (82–90) 97% (93–98) 97% (90–99)
5-year SFU 80% (75–85) 89% (83–93) 92% (79–97)
10-year SFU 72% (65–77) 82% (71–89) Not estimable
Data are estimated percentage (95% CI). Seizure freedom or continuation was 
deﬁ ned every year on the anniversary of surgery. SFU=subsequent follow-up.
Table 5: People remaining seizure free after continuous periods of 
postsurgical seizure freedom, estimated by survival analysis, at each 
subsequent follow-up
Ongoing seizures for 
2 years after surgery 
(n=108)
Ongoing seizures for 
5 years after surgery 
(n=69)
1 year SFU 6% (3–13) 1% (0–10)
2 year SFU 13% (8–21) 8% (3–18)
5 year SFU 24% (16–34) 20% (12–33)
10 year SFU 38% (28–51) 30% (17–50)
Data are estimated percentage (95% CI). Seizure freedom or continuation was 
deﬁ ned every year on the anniversary of surgery. SFU=subsequent follow-up.
Table 6: People gaining 1 year of seizure freedom after continuous 
periods of ongoing seizures, estimated by survival analysis, at each 
subsequent follow-up
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We showed that almost three-quarters of people had at 
least 1 year of absolute seizure freedom at some stage, 
which increased to 82% if SPS were discounted. 18% had 
no seizure freedom for 1 year, at any time. Another study12 
noted that by 2 years, 70% had a remission (with or without 
SPS) of 1 year, 74% by 3 years, and 77% by 5 years. 
We found that people with extratemporal resections 
had a greater probability of seizure recurrence than did 
those with anterior temporal resection. Similar ﬁ ndings 
were reported in a long-term follow-up study15 of patients 
after surgery in which those who had temporal resections 
were at an increased chance of seizure freedom. 
In our study, in people who had anterior temporal 
resection, those with focal cortical dysplasia, and those 
with other pathological changes, including other malfor-
mations and no detected abnormality, were more likely to 
have recurrent seizures than were those with hippo campal 
sclerosis, although numbers are small. Other studies10,15 
have also reported a more favourable outcome in people 
with hippocampal sclerosis. Our 5-year rates of seizure 
freedom (excluding SPS) for anterior temporal resection 
were 57% for patients with hippocampal sclerosis, and 
63% for those with dysembryoplastic neuroepithelial 
tumour. A study16 of postoperative outcome in patients 
with pathological changes identiﬁ ed with preoperative 
MRI showed that a 2-year terminal remission was obtained 
in 80% of patients with tumours and vascular malfor-
mations, 58% with hippocampal sclerosis, and 29% of 
those with normal MRI. However, an assessment17 of 
people who had anterior temporal resection showed that 
the underlying pathological changes did not deter mine 
time to subsequent ﬁ rst seizure. The presence of 
ganglioglioma or dysembryoplastic neuroepithelial 
tumour, and absence of dysplasia have been associated 
with good postoperative control of seizures.18
We showed that for equivalent pathological changes 
(glioma, dysembryoplastic neuroepithelial tumour, 
caver noma, or focal cortical dysplasia), temporal 
lesionectomies and anterior temporal resection had 
similar rates of seizure freedom. In an analysis18 of 
people aged between 2 years and 62 years with temporal 
lobe epilepsy, no diﬀ erence in postoperative outcome 
was noted between people who had anterior temporal 
resection with hippocampectomy, amygdalohippo-
campectomy, lateral temporal lesionectomy with 
corticectomy, or lesionectomy with corticectomy and 
hippocampectomy. However, in another study of 
children19 those who had amygdalohippo campectomy 
had signiﬁ cantly lower rates of seizure freedom than did 
those who had standard anterior temporal resection. In 
patients with dys embryoplastic neuroepithelial tumour,20 
those with temporal resection were more likely to be 
seizure free than were those who had lesionectomy, but 
the lesion was not temporal in most patients. 
The probability of patients in our study remaining 
seizure free increased with the number of years of seizure 
freedom already experienced (table 5). This ﬁ nding is 
supported by results from a study12 of outcome after 
temporal surgery in which individuals who were seizure 
free (or with SPS only) for any 1 year had a 90% probability 
of having no seizures in the next year, and those with 
2 successive years of seizure freedom had a 94% chance 
of seizure freedom in the subsequent year. Others found 
that the probability of remaining seizure free for a mean 
of 5·6 years follow-up was 83% in those who were seizure 
free for the ﬁ rst year after temporal surgery, and 92% in 
those seizure free for the ﬁ rst 2 post-operative years.11 In 
another study,21 in people seizure free with or without 
SPS for 1 year after surgery, the probability of subsequently 
having a seizure was estimated to be 18% at 5 years and 
33% at 10 years. 
Panel 2: Research in context
Systematic review
We did a review to ascertain results of previous studies of the 
outcome after epilepsy surgery. We searched Medline and 
Embase from Jan 1, 1990, to March 30, 2011 for published 
papers reporting outcome with the search term “epilepsy 
surgery outcome”. We excluded articles not written in English.
Interpretation
A meta-analysis8 summarised previous studies of epilepsy 
surgery outcome in which 66% of people were seizure free 
in the long term after temporal resections with poorer 
results for those with other types of surgery. Many studies 
reported seizure freedom at the end of follow-up rather 
than sustained seizure freedom. We have reported 
long-term results and have looked at strictly long-term 
outcomes in terms of time to ﬁ rst seizure and ongoing 
seizure patterns. We have shown that 40% are entirely 
seizure free from surgery; whereas at any timepoint about 
70% are free of disabling seizures, and every year up to 
15% change their seizure status.
There are ﬁ ve clinical messages. First, 40% have long-term 
complete seizure freedom after epilepsy surgery, with a 
further 11% having only SPS. Although 82% had at least 1 year 
with no seizures or only SPS, this does not indicate cure. No 
patient had substantial worsening of epilepsy. Clinical practice 
should change to sooner refer appropriate patients for 
possible surgery. Second, selection process and surgical 
methods need improvement to increase success rates and to 
more accurately identify those who will not beneﬁ t from 
surgery. Some studies could have implied overoptimistic 
expectations. Third, if SPS continue in the ﬁ rst 2 years after 
surgery, the probability of seizures recurring was twice that if 
the person was entirely seizure free; previous studies have not 
reported this ﬁ nding. Such important information might 
aﬀ ect the decision to taper or continue antiepileptic drugs. 
Fourth, anterior temporal resection was associated with a 
higher probability of seizure freedom than resections in other 
parts of the brain. Finally, most people who are seizure free 
after surgery choose to remain on an antiepileptic drug.
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In our study, patients with SPS in the ﬁ rst 2 years were 
twice as likely to have subsequent seizures with impaired 
awareness as were those entirely SPS free. Another 
study22 examined people who had SPS associated with 
complex partial or secondarily generalised seizures 
before temporal resections. In that study,22 follow up of 
patients who were free of complex partial or secondarily 
generalised seizures for 2 years after surgery showed no 
diﬀ erence in terms of subsequent freedom from these 
seizures between patients who did and did not have 
postoperative SPS. 
Our ﬁ ndings show that even in people with a long 
period of continuing seizures, the possibility of 
remission remains (table 6), and a few individuals 
became seizure free after the introduction of new 
antiepileptic drugs. The antiepileptic drugs introduced 
after surgery in our study had not been tried previously, 
and we cannot know whether they could have controlled 
seizures if used pre-operatively.
Follow-up23 of 276 people who had at least one seizure 
after the immediate postoperative period noted that 
77% would have further seizures within 12 months and, 
after a second seizure, 86% would have further seizures 
within 12 months. A third of patients subsequently had 
one or more seizure-free years. A study24 of 86 people 
with temporal epilepsy who still had seizures 6 months 
after surgery found that 32% had been seizure free for at 
least 1 year by 2-year follow-up. In another study,25 of 
51 people who had anterior temporal resection, 27% had 
seizures in the ﬁ rst 2 years and 29% of these became 
seizure free in the third and fourth postoperative years. 
28% of our patients who were seizure free at last follow-
up stopped antiepileptic drugs. Others might have been 
suitable for drug reduction but have been reluctant to do 
so (often for social reasons, such as permission to drive). 
In a future analysis, we will consider reduction of 
antiepileptic drugs and factors aﬀ ecting this. 
Our study had several limitations. Caveats to the 
assessment of outcome according to operative procedure 
in people with temporal surgery were the small numbers, 
that the decision was not randomly assigned, and that 
patients with extensive disease and lesions close to the 
hippocampus were more likely to have anterior temporal 
resection than were other patients. Additionally, because 
of the small numbers and the observational nature of our 
study we cannot comment strongly on use of antiepileptic 
drugs, but note that if seizures continue after surgery, new 
drugs could be considered. 
In our study, incidence of mortality and new morbidity 
after epilepsy surgery was low and compares favourably 
with the annual mortality rate of severe epilepsy.7 
Goldmann perimetry is more sensitive than clinical 
assessment and visual ﬁ eld defects have been detected 
in up to 42% of patients after temporal resection at 
NHNN.26,27 Separate reports will establish the eﬀ ects of 
surgery on cognitive function, psychiatric status, 
and employment.
Our cohort was highly selected. Although most patients 
showed a substantial reduction in seizures, only 40% 
entered long-term remission by virtue of having no 
seizures from time of surgery, and only 28% of those 
who were seizure free at last follow-up had discontinued 
antiepileptic drugs and could therefore be regarded as 
being cured. The procedures and process of epilepsy 
surgery at NHNN are similar to those at other major 
epilepsy surgery centres and as such could be 
generalisable, but replication at other centres would be 
valuable. Consideration of either pregnancy or obtaining 
a driving licence seem to be major factors in an 
individual’s decision making, and no prospective 
randomised trial is available of cessation or continuation 
of antiepileptic drugs after surgery.
For seizure outcome, surgery is successful for many 
individuals in whom antiepileptic drugs have not been 
eﬀ ective, but further improvements need to be made to 
presurgical assessment to further increase rates of success 
(panel 2).
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